Literature DB >> 7284242

A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.

J R Johnson, C H Ford, C E Newman, C S Woodhouse, G F Rowland, R G Simmonds.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7284242      PMCID： PMC2010775          DOI： 10.1038/bjc.1981.209

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

1.  Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody.

Authors:  T Ghose; S T Norvell; A Guclu; A S Macdonald
Journal:  Eur J Cancer       Date:  1975-05       Impact factor: 9.162

Review 2.  Antibodies as specific carriers for chemotherapeutic agents.

Authors:  F H Lee; K M Hwang
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  [3H]Uridine uptake by target monolayers as a terminal label in an in vitro cell-mediated cytotoxicity assay.

Authors:  G Smith; S Nicklin
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

4.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

5.  Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.

Authors:  R A Conrad; G J Cullinan; K Gerzon; G A Poore
Journal:  J Med Chem       Date:  1979-04       Impact factor: 7.446

Review 6.  Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects.

Authors:  T Ghose; A H Blair
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

7.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

Authors:  L M Nadler; P Stashenko; R Hardy; W D Kaplan; L N Button; D W Kufe; K H Antman; S F Schlossman
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

8.  Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen.

Authors:  P W Dykes; K R Hine; A R Bradwell; J C Blackburn; T A Reeder; Z Drolc; S N Booth
Journal:  Br Med J       Date:  1980-01-26

9.  Antibody-drug synergism: An assessment of specific passive immunotherapy in bronchial carcinoma.

Authors:  C E Newman; C H Ford
Journal:  Lancet       Date:  1977-07-23       Impact factor: 79.321

10.  Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation.

Authors:  J P Mach; S Carrel; M Forni; J Ritschard; A Donath; P Alberto
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245
  10 in total
  8 in total

1.  Is there a role for radioimmunolocalization in diagnosis of intracranial malignancies?: discussion paper.

Authors:  J T Kemshead; D H Jones; A Goldman; R B Richardson; H B Coakham
Journal:  J R Soc Med       Date:  1984-10       Impact factor: 5.344

Review 2.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Antitumor properties of vindesine-monoclonal antibody conjugates.

Authors:  G F Rowland; C A Axton; R W Baldwin; J P Brown; J R Corvalan; M J Embleton; V A Gore; I Hellström; K E Hellström; E Jacobs
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.

Authors:  M J Embleton; G F Rowland; R G Simmonds; E Jacobs; C H Marsden; R W Baldwin
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

Review 5.  Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency.

Authors:  Sang-Woo Kim; Dongwoo Khang
Journal:  Int J Nanomedicine       Date:  2015-06-17

6.  Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol.

Authors:  K Takashina; K Kitamura; T Yamaguchi; A Noguchi; A Noguchi; H Tsurumi; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1991-10

7.  The effect of an anti-membrane antibody-methotrexate conjugate on the human prostatic tumour line PC3.

Authors:  A J Rowland; M E Harper; D W Wilson; K Griffiths
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

8.  Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

Authors:  C H Ford; C E Newman; J R Johnson; C S Woodhouse; T A Reeder; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.